Table 2.
Adherence to the scheduled chemotherapy.
| Once-a-week group (N = 250) | Once-every-3-weeks group (N = 260) | |
|---|---|---|
| No. of patients randomized | 250 | 260 |
| Patients starting CCRT, no. (%) | 250 (100.0%) | 260 (100.0%) |
| Total no. of cycles given, n (%) | ||
| Zero cycle | 1 (0.4%) | 0 |
| One cycle | 1 (0.4%) | 1 (0.4%) |
| Two cycles | 2 (0.8%) | 259 (99.6%) |
| Three cycles | 1 (0.4%) | - |
| Four cycles | 19 (7.6%) | - |
| Five cycles | 92 (36.8%) | - |
| Six cycles | 134 (53.6%) | - |
| Patients receiving reduced dose | 124 (49.6%) | 26 (10.0%) |
| Total cisplatin dose given, mg/m2 | ||
| <100 | 4 (1.6%) | 0 |
| ≥100 and <200 | 30 (12.0%) | 26 (10.0%) |
| ≥200 | 216 (86.4%) | 234 (90.0%) |
| Median dose (IQR) | 220 (198–240) | 200 (200–200) |
Abbreviations: CCRT, concurrent chemoradiotherapy; IQR, interquartile range.